A SURVEY OF RHEUMATOLOGY PATIENTS' SATISFACTION TO SWITCHING FROM ORIGINATOR TO BIOSIMILAR AGENTS

被引：0
|
作者：
Ng, C. R. [1 ]
Samec, S. [1 ]
Kavanagh, P. [1 ]
Mccarthy, G. [1 ]
Donnelly, S. [1 ]
Wilson, A. G. [1 ]
机构：
[1] Mater Misericordiae Univ Hosp, Dept Rheumatol, Dublin, Ireland
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2021年 / 80卷
关键词：
D O I：
10.1136/annrheumdis-2021-eular.2981
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
AB0805
引用
收藏
页码：1427 / 1427
页数：1
相关论文
共 50 条
  • [31] Switching between biosimilars and originator in hidradenitis suppurativa: retrospective study on biosimilar failure after originator
    Cannizzaro, Maria Vittoria
    Maffei, Virginia
    Shumak, Ruslana Gaeta
    Lambiase, Sara
    Pensa, Chiara
    Botti, Elisabetta
    Bianchi, Luca
    EXPERIMENTAL DERMATOLOGY, 2022, 31 : 113 - 114
  • [32] Efficacy, Pharmacokinetics, and Immunogenicity is Not Affected by Switching From Infliximab Originator to a Biosimilar in Pediatric Patients With Inflammatory Bowel Disease
    van Hoeve, Karen
    Dreesen, Erwin
    Hoffman, Ilse
    Van Assche, Gert
    Ferrante, Marc
    Gils, Ann
    Vermeire, Severine
    THERAPEUTIC DRUG MONITORING, 2019, 41 (03) : 317 - 324
  • [33] Switching from adalimumab originator to ABP 501 biosimilar: a multicentre North Italian study
    Barberio, B.
    Melatti, P.
    Zingone, F.
    Bertani, L.
    Ferronato, A.
    Gubbiotti, A.
    Massimi, D.
    D'Inca, R.
    Savarino, E. V.
    JOURNAL OF CROHNS & COLITIS, 2020, 14 : S414 - S414
  • [34] OUTCOMES FOLLOWING SWITCHING FROM ORIGINATOR TO BIOSIMILAR PRODUCT IN CHILDREN AND YOUNG PEOPLE WITH JIA
    Kearsley-Fleet, Lianne
    Baildam, Eileen
    Beresford, Michael W.
    Douglas, Sharon
    Foster, Helen E.
    Southwood, Taunton R.
    Hyrich, Kimme L.
    RHEUMATOLOGY, 2023, 62
  • [35] REAL-WORLD EXPERIENCE OF SWITCHING FROM ORIGINATOR TO BIOSIMILAR RITUXIMAB IN RHEUMATOID ARTHRITIS
    Melville, A.
    Yusof, M. Y. Md
    Fitton, J.
    Bailey, L.
    Emery, P.
    Buch, M. H.
    Dass, S.
    Saleem, B.
    ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 : 299 - 300
  • [36] Switching From Originator to Biosimilar Infliximab in Paediatric Inflammatory Bowel Disease Is Feasible and Uneventful
    Gervais, Lisa
    McLean, Luke L.
    Wilson, Michelle L.
    Cameron, Carol
    Curtis, Lee
    Garrick, Vikki
    Armstrong, Kat
    Tayler, Rachel
    Henderson, Paul
    Hansen, Richard
    Chalmers, Iain
    Wilson, David C.
    Russell, Richard K.
    JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION, 2018, 67 (06): : 745 - 748
  • [37] Switching from adalimumab originator to biosimilar: a 3-year retrospective cohort analysis
    Killion, Lisa
    Alsharqi, Ali
    Kirby, Brian
    BRITISH JOURNAL OF DERMATOLOGY, 2023, 188
  • [38] HIGH RATES OF CLINICAL RESPONSE ARE MAINTAINED AFTER SWITCHING FROM ORIGINATOR TO BIOSIMILAR INFLIXIMAB
    Haggarty, Rebecca
    Waddell, Katy
    Veryan, Jennifer
    Nowell, Emma
    Seenan, John Paul
    Macdonald, Jonathan
    GUT, 2019, 68 : A101 - A101
  • [39] Switching from adalimumab originator to biosimilar: a 3-year retrospective cohort analysis
    Killion, Lisa
    Alsharqi, Ali
    Kirby, Brian
    CLINICAL AND EXPERIMENTAL DERMATOLOGY, 2023, 48 (04) : 397 - 398
  • [40] Switching Patterns Among Patients with Chronic Inflammatory Diseases Switching to an Infliximab Biosimilar or Remaining on Originator Infliximab (REMICADE)
    Emond, Bruno
    Sadik, Kay
    Lafeuille, Marie-Helene
    Wynant, Willy
    Cote-Sergent, Aurelie
    Lefebvre, Patrick
    Woodruff, Kimberly
    Fitzgerald, Timothy
    ARTHRITIS & RHEUMATOLOGY, 2019, 71
12345